A Phase 3 interventional study of Dupilumab (SAR231893/REGN668) and Asthma controller therapies (incl. prednisone/prednisolone) in Asthma, sponsored by Sanofi. Completed at 81 sites in 18 countries. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2025-11-21.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing dupilumab in Asthma — 7 open to participants now, 12 under way, 2 of them phase 3. dupilumab · Asthma.
Among the 31 studies testing dupilumab in Asthma, this one is the 8th largest by enrollment, is one of 2 that started in 2018, is one of 11 in phase 3, and was the 9th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →7 of the 31 studies testing dupilumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
Université de Sherbrooke · Sites in Australia, Canada, United Kingdom
Ages 18–79
University Hospital, Toulouse · Sites in France
Ages 18+
University of California, San Diego · Sites in United States
Ages 18–75
Sally E. Wenzel MD · Sites in United States
Ages 18+
University of Virginia · Sites in United States
Ages 18–40
By country, each count listing its studies:
dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 6 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dupilumab is the treatment under test here. Read study by study →
31 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2018.
This study's enrollment of 378 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 120 across the 31 interventional studies. Of the 17 that completed or were terminated, 14 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 31 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
37 studies in Asthma by Sanofi: 3 open now, 5 under way, 1 of them phase 3. Of 32 finished, 14 (44%) have results posted.
Among the 37 studies in Asthma by Sanofi, this one is the 20th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2018, is one of 16 in phase 3, and was the 18th registered.
Sanofi’s Asthma studies by the year they started, since 2000.
5 of the studies testing dupilumab in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05347771National Institute of Allergy and Infectious Diseases (NIAID)Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents | 2026-12-31 |
| NCT03694158Boston Children's HospitalInvestigating Dupilumab's Effect in Asthma by Genotype | 2027-01 |
| NCT05097287SanofiStudy Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma | 2027-03-16 |
| NCT06572228Regeneron PharmaceuticalsEfficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma | 2027-04-24 |
| NCT06385236University of California, San DiegoLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 31 studies testing dupilumab in Asthma, from their registry updates:
Among Sanofi’s 37 in Asthma:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
Secondary Objectives:
To evaluate dupilumab in pediatric patients with asthma who participated in a previous dupilumab asthma clinical study with regard to:
To evaluate dupilumab in pediatric patients with asthma in the Japan substudy with regard to:
Study duration per participant is approximatively 64 weeks including a 52 weeks treatment period and 12 weeks post treatment follow-up.
Japan substudy:
Study duration per participant is approximately 68 weeks including 3-5 weeks screening period, 52 weeks treatment period and 12 weeks post treatment follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who are not able to complete their treatment in Study EFC14153 due to the COVID-19 pandemic will be allowed to enroll into Study LTS14424. Patients who enroll in LTS14424 after completing the EFC14153 EOS visit should have eligibility for LTS14424 reevaluated including background medication check and laboratory assessments (including complete blood count [CBC] with differential and basic chemistry) within 1 month prior to LTS14424 Visit 1.
For Japan sub-study
Exclusion criteria:
For Japan sub-study:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Doses of dupilumab will be administered every 2 weeks or every 4 weeks added to current controller medications for 52 weeks
Drug: Dupilumab (SAR231893/REGN668) · Drug: Asthma controller therapies (incl. prednisone/prednisolone) · Drug: Asthma reliever therapies
Drug page: Dupilumab
Pharmaceutical form: solution for injection Route of administration: subcutaneous (sc)
Pharmaceutical form: powder, or solution, or pill Route of administration: inhaled, oral or parenteral
Pharmaceutical form: powder or solution Route of administration: inhaled
Main Study: Number of Participants With Any Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. TEAEs were AEs that developed or worsened or became serious during the TEAE period.
Time frame: From first dose of study treatment (Day 1) up to 112 days post last dose of study treatment, approximately 64 weeks
Japan Sub-study: Change From Baseline to Week 12 in Pre-Bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second (FEV1)
FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Spirometry was performed after a wash out period of bronchodilators according to their action duration. Baseline was defined as the last available measurement prior to the first study treatment dose if the participant was treated, or the last available value up to enrollment if the participant was not exposed to study treatment in the current study.
Time frame: Baseline (Day 1) to Week 12
Japan Sub-study: Number of Participants With Any Treatment-Emergent Adverse Events
An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. TEAEs were AEs that developed or worsened or became serious during the TEAE period.
Time frame: From first dose of study treatment (Day 1) up to 112 days post last dose of study treatment, approximately 64 weeks
Annualized Rate of Severe Asthma Exacerbation Events During the 52-Week Treatment Period
A severe exacerbation event during study was defined as a deterioration of asthma requiring use of systemic corticosteroid (SCS) for ≥3 days or hospitalization/emergency room visit because of asthma, requiring SCS. Annualized severe exacerbation event rate was defined as total number of events that occurred during 52-week treatment period divided by total number of participant-years followed in 52-week treatment period.
Time frame: Up to Week 52
Change From Baseline in Pre-Bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second Over Time
FEV1 was volume of air (in liters) exhaled from the lungs in first second of a forced expiration as measured by spirometer. Spirometry was performed after a wash out period of bronchodilators according to their action duration. Baseline (main study): original baseline of parent study EFC14153. Baseline (sub-study): last available measurement prior to first study treatment dose if participant was treated, or last available value up to enrollment if participant was not exposed to study treatment in current study.
Time frame: Baseline (Day 1) and Weeks 2, 4 (Japan sub-study), 8, 12, 24, 52 and 64
Change From Baseline in Absolute Forced Expiratory Volume in 1 Second Over Time
FEV1 was volume of air (in liters) exhaled from the lungs in first second of a forced expiration as measured by spirometer. Spirometry was performed after a wash out period of bronchodilators according to their action duration. Baseline (main study): original baseline of parent study EFC14153. Baseline (sub-study): last available measurement prior to first study treatment dose if participant was treated, or last available value up to enrollment if participant was not exposed to study treatment in current study.
Time frame: Baseline (Day 1) and Weeks 2, 4 (Japan sub-study), 8, 12, 24, 52 and 64
Change From Baseline in Forced Vital Capacity (FVC) Over Time
FVC was defined as volume of air (in liters) that could be forcibly blown out after full inspiration in upright position as measured by spirometer. Spirometry was performed after wash out period of bronchodilators according to their action duration. Baseline (main study):original baseline of parent study EFC14153. Baseline (sub-study): last available measurement prior to first study treatment dose if participant was treated or last available value up to enrollment if participant was not exposed to study treatment in current study.
Time frame: Baseline (Day 1) and Weeks 2, 4 (Japan sub-study), 8, 12, 24, 52 and 64
Change From Baseline in Forced Expiratory Flow [FEF] 25% to 75% Over Time
FEF was defined as amount of air which can be forcibly exhaled from lungs in first second of forced exhalation. FEF 25-75% was the mean FEF between 25% and 75% of FVC. FVC was defined as volume of air that could be forcibly blown out after full inspiration in upright position. Spirometry was performed after wash out period of bronchodilators. Baseline (main study): original baseline of parent study EFC14153. Baseline (sub-study): last available measurement prior to first study treatment dose if participant was treated or last available value up to enrollment if participant was not exposed to study treatment in current study.
Time frame: Baseline (Day 1) and Weeks 2, 4 (Japan sub-study), 8, 12, 24, 52 and 64
Main Study: Change From Baseline in Percent Predicted Forced Vital Capacity Over Time
FVC was defined as volume of air (in liters) that could be forcibly blown out after full inspiration in upright position as measured by spirometer. Spirometry was performed after wash out period of bronchodilators according to their action duration. Baseline was defined as the original baseline of parent study EFC14153.
Time frame: Baseline (Day 1) and Weeks 2, 8, 12, 24, 52 and 64
Japan Sub-study: Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 7-Question Version (ACQ-7-IA) Over Time
ACQ-7-IA had 7 questions with first 5 items of ACQ-7 addressing most common asthma symptoms: frequency in past week awoken by asthma during night, severity of asthma symptoms in morning, limitation of daily activities due to asthma, shortness of breath due to asthma, wheeze; 2 questions on short-acting bronchodilator use and predicted bronchodilator use of FEV1. Participants/parents/guardians recalled child's previous week asthma and responded to questions on 7-point scale: 0=no impairment, 6=maximum impairment. Global ACQ-7-IA score was the mean of 7 questions, ranging from 0 (totally controlled) to 6 (severely uncontrolled). Higher scores indicated lower asthma control. Baseline: last available measurement prior to first study treatment dose if participant was treated or last available value up to enrollment if participant was not exposed to study treatment in current study.
Time frame: Baseline (Day 1) and Weeks 2, 4, 8, 12, 24, 36, 52 and 64
Japan Sub-study: Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 5-Question Version (ACQ-5-IA) Over Time
The ACQ-5-IA had 5 questions addressing most common asthma symptoms: frequency in past week awoken by asthma during night, severity of asthma symptoms in morning, limitation of daily activities due to asthma, shortness of breath due to asthma and wheeze. Participants/parents/guardians recalled the child's previous week asthma and responded to symptom and bronchodilator use questions on a 7-point scale: 0=no impairment, 6=maximum impairment. Global ACQ-5-IA score was the mean of 5 questions, ranging from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control. Baseline: last available measurement prior to first study treatment dose if participant was treated, or last available value up to enrollment if participant was not exposed to study treatment in current study.
Time frame: Baseline (Day 1) and Weeks 2, 4, 8, 12, 24, 36, 52 and 64
Serum Concentrations of Dupilumab
Blood samples were collected at the specified timepoints for determination of functional dupilumab concentration in serum.
Time frame: Weeks 12, 24, 52 and 64
Number of Participants With Anti-Drug Antibodies (ADAs) Against Dupilumab
ADA positive was defined as either treatment-boosted or treatment-emergent response in the ADA assay. Treatment-boosted response was defined as a positive response in the ADA assay post first dose in the current study that was greater than or equal to 4-fold of the baseline titer levels, when baseline results were positive. Treatment-emergent response was defined as a positive response in the ADA assay post first dose in the current study, when baseline results were negative or missing. Baseline (main study): original baseline of parent study EFC14153. Baseline (sub-study): last available measurement prior to first study treatment dose if participant was treated, or last available value up to enrollment if participant was not exposed to study treatment in current study.
Time frame: From first dose of study treatment (Day 1) to Week 64
Main Study: Percent Change From Baseline in Blood Eosinophil Count at Week 64
Blood samples were collected at specified timepoints to assess percent change from baseline in eosinophil count. Baseline was defined as the original baseline of parent study EFC14153.
Time frame: Baseline (Day 1) to Week 64
Percent Change From Baseline in Total Immunoglobulin (Ig) E in Serum at Week 64
Blood samples were collected at specified timepoints to assess percent change from baseline in total IgE in serum. Baseline (main study): the original baseline of parent study EFC14153. Baseline (sub-study): last available measurement prior to first study treatment dose if participant was treated, or last available value up to enrollment if participant was not exposed to study treatment in current study.
Time frame: Baseline (Day 1) to Week 64
Japan Sub-study: Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 64
FeNO was analyzed using a NIOX instrument or similar analyzer using a flow rate of 50 milliliter per second. FeNO assessment was conducted prior to spirometry and following a fast of ≥1 hour. Baseline was defined as the last available measurement prior to first study treatment dose if participant was treated, or last available value up to enrollment if participant was not exposed to study treatment in the current study.
Time frame: Baseline (Day 1) to Week 64
The main study was conducted at 70 centers in 17 countries, and the sub-study was conducted at 11 centers in Japan. 365 participants who rolled over from parent study EFC14153 (NCT02948959) were enrolled in the main study and 13 participants (not included in parent study EFC14153) were enrolled in Japan sub-study.
| Milestone | Main Study: Placebo-Dupilumab | Main Study: Dupilumab-Dupilumab | Japan Sub-study: Dupilumab |
|---|---|---|---|
| Started | 125 | 240 | 13 |
| Completed | 118 | 228 | 12 |
| Not completed | 7 | 12 | 1 |
| Withdrew: Adverse event | 1 | 2 | 0 |
| Withdrew: Poor compliance to protocol | 0 | 2 | 0 |
| Withdrew: Other | 6 | 8 | 1 |
An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. TEAEs were AEs that developed or worsened or became serious during the TEAE period.
| Participants | Main Study: Placebo-Dupilumab | Main Study: Dupilumab-Dupilumab |
|---|---|---|
| Main Study: Number of Participants With Any Treatment-Emergent Adverse Events (TEAEs) | 85 | 147 |
FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Spirometry was performed after a wash out period of bronchodilators according to their action duration. Baseline was defined as the last available measurement prior to the first study treatment dose if the participant was treated, or the last available value up to enrollment if the participant was not exposed to study treatment in the current study.
| percent predicted FEV1 | Japan Sub-study: Dupilumab |
|---|---|
| Japan Sub-study: Change From Baseline to Week 12 in Pre-Bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) | 7.08 ± 6.78 |
An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. TEAEs were AEs that developed or worsened or became serious during the TEAE period.
| Participants | Japan Sub-study: Dupilumab |
|---|---|
| Japan Sub-study: Number of Participants With Any Treatment-Emergent Adverse Events | 13 |
A severe exacerbation event during study was defined as a deterioration of asthma requiring use of systemic corticosteroid (SCS) for ≥3 days or hospitalization/emergency room visit because of asthma, requiring SCS. Annualized severe exacerbation event rate was defined as total number of events that occurred during 52-week treatment period divided by total number of participant-years followed in 52-week treatment period.
| exacerbations per participant-years | Main Study: Placebo-Dupilumab | Main Study: Dupilumab-Dupilumab | Japan Sub-study: Dupilumab |
|---|---|---|---|
| Annualized Rate of Severe Asthma Exacerbation Events During the 52-Week Treatment Period | 0.114 | 0.120 | 0.462 |
FEV1 was volume of air (in liters) exhaled from the lungs in first second of a forced expiration as measured by spirometer. Spirometry was performed after a wash out period of bronchodilators according to their action duration. Baseline (main study): original baseline of parent study EFC14153. Baseline (sub-study): last available measurement prior to first study treatment dose if participant was treated, or last available value up to enrollment if participant was not exposed to study treatment in current study.
| percent predicted FEV1 | Main Study: Placebo-Dupilumab | Main Study: Dupilumab-Dupilumab | Japan Sub-study: Dupilumab |
|---|---|---|---|
| Week 2 | 8.06 ± 15.71 | 11.03 ± 18.74 | 7.50 ± 9.29 |
| Week 4 | — | — | 7.00 ± 7.12 |
| Week 8 | 7.93 ± 14.88 | 12.47 ± 18.60 | 6.31 ± 8.97 |
| Week 12 | 8.31 ± 14.70 | 10.95 ± 17.33 | 7.08 ± 6.78 |
| Week 24 | 8.37 ± 15.48 | 11.23 ± 18.24 | 4.08 ± 8.75 |
| Week 52 | 8.81 ± 16.18 | 12.19 ± 17.88 | 6.73 ± 8.09 |
| Week 64 | 7.98 ± 17.14 | 10.67 ± 17.19 | 1.17 ± 8.03 |
FEV1 was volume of air (in liters) exhaled from the lungs in first second of a forced expiration as measured by spirometer. Spirometry was performed after a wash out period of bronchodilators according to their action duration. Baseline (main study): original baseline of parent study EFC14153. Baseline (sub-study): last available measurement prior to first study treatment dose if participant was treated, or last available value up to enrollment if participant was not exposed to study treatment in current study.
| liter | Main Study: Placebo-Dupilumab | Main Study: Dupilumab-Dupilumab | Japan Sub-study: Dupilumab |
|---|---|---|---|
| Week 2 | 0.36 ± 0.32 | 0.42 ± 0.38 | 0.13 ± 0.15 |
| Week 4 | — | — | 0.13 ± 0.13 |
| Week 8 | 0.38 ± 0.32 | 0.47 ± 0.39 | 0.12 ± 0.15 |
| Week 12 | 0.41 ± 0.31 | 0.45 ± 0.36 | 0.17 ± 0.13 |
| Week 24 | 0.46 ± 0.35 | 0.51 ± 0.39 | 0.15 ± 0.15 |
| Week 52 | 0.62 ± 0.41 | 0.66 ± 0.41 | 0.34 ± 0.21 |
| Week 64 | 0.66 ± 0.45 | 0.70 ± 0.44 | 0.25 ± 0.14 |
FVC was defined as volume of air (in liters) that could be forcibly blown out after full inspiration in upright position as measured by spirometer. Spirometry was performed after wash out period of bronchodilators according to their action duration. Baseline (main study):original baseline of parent study EFC14153. Baseline (sub-study): last available measurement prior to first study treatment dose if participant was treated or last available value up to enrollment if participant was not exposed to study treatment in current study.
| liter | Main Study: Placebo-Dupilumab | Main Study: Dupilumab-Dupilumab | Japan Sub-study: Dupilumab |
|---|---|---|---|
| Week 2 | 0.35 ± 0.29 | 0.38 ± 0.38 | 0.11 ± 0.15 |
| Week 4 | — | — | 0.09 ± 0.12 |
| Week 8 | 0.37 ± 0.30 | 0.45 ± 0.42 | 0.11 ± 0.14 |
| Week 12 | 0.40 ± 0.30 | 0.43 ± 0.39 | 0.12 ± 0.11 |
| Week 24 | 0.47 ± 0.36 | 0.50 ± 0.40 | 0.17 ± 0.15 |
| Week 52 | 0.68 ± 0.42 | 0.70 ± 0.45 | 0.36 ± 0.22 |
| Week 64 | 0.74 ± 0.49 | 0.75 ± 0.48 | 0.41 ± 0.24 |
FEF was defined as amount of air which can be forcibly exhaled from lungs in first second of forced exhalation. FEF 25-75% was the mean FEF between 25% and 75% of FVC. FVC was defined as volume of air that could be forcibly blown out after full inspiration in upright position. Spirometry was performed after wash out period of bronchodilators. Baseline (main study): original baseline of parent study EFC14153. Baseline (sub-study): last available measurement prior to first study treatment dose if participant was treated or last available value up to enrollment if participant was not exposed to study treatment in current study.
| liter per second | Main Study: Placebo-Dupilumab | Main Study: Dupilumab-Dupilumab | Japan Sub-study: Dupilumab |
|---|---|---|---|
| Week 2 | 0.49 ± 0.63 | 0.58 ± 0.66 | 0.21 ± 0.26 |
| Week 4 | — | — | 0.25 ± 0.23 |
| Week 8 | 0.48 ± 0.60 | 0.62 ± 0.63 | 0.15 ± 0.30 |
| Week 12 | 0.54 ± 0.60 | 0.59 ± 0.61 | 0.29 ± 0.31 |
| Week 24 | 0.58 ± 0.68 | 0.66 ± 0.65 | 0.15 ± 0.37 |
| Week 52 | 0.73 ± 0.75 | 0.77 ± 0.67 | 0.40 ± 0.46 |
| Week 64 | 0.77 ± 0.78 | 0.79 ± 0.70 | 0.11 ± 0.34 |
FVC was defined as volume of air (in liters) that could be forcibly blown out after full inspiration in upright position as measured by spirometer. Spirometry was performed after wash out period of bronchodilators according to their action duration. Baseline was defined as the original baseline of parent study EFC14153.
| percent predicted FVC | Main Study: Placebo-Dupilumab | Main Study: Dupilumab-Dupilumab |
|---|---|---|
| Week 2 | 2.98 ± 12.91 | 5.02 ± 16.33 |
| Week 8 | 2.88 ± 12.17 | 6.64 ± 17.42 |
| Week 12 | 3.23 ± 12.49 | 5.03 ± 16.45 |
| Week 24 | 3.19 ± 13.35 | 5.28 ± 16.20 |
| Week 52 | 3.74 ± 13.10 | 6.43 ± 16.40 |
| Week 64 | 3.13 ± 15.14 | 4.83 ± 16.09 |
ACQ-7-IA had 7 questions with first 5 items of ACQ-7 addressing most common asthma symptoms: frequency in past week awoken by asthma during night, severity of asthma symptoms in morning, limitation of daily activities due to asthma, shortness of breath due to asthma, wheeze; 2 questions on short-acting bronchodilator use and predicted bronchodilator use of FEV1. Participants/parents/guardians recalled child's previous week asthma and responded to questions on 7-point scale: 0=no impairment, 6=maximum impairment. Global ACQ-7-IA score was the mean of 7 questions, ranging from 0 (totally controlled) to 6 (severely uncontrolled). Higher scores indicated lower asthma control. Baseline: last available measurement prior to first study treatment dose if participant was treated or last available value up to enrollment if participant was not exposed to study treatment in current study.
| score on a scale | Japan Sub-study: Dupilumab |
|---|---|
| Week 2 | -0.65 ± 0.64 |
| Week 4 | -0.68 ± 0.75 |
| Week 8 | -0.84 ± 0.59 |
| Week 12 | -1.03 ± 0.66 |
| Week 24 | -0.96 ± 0.61 |
| Week 36 | -1.01 ± 0.47 |
| Week 52 | -1.21 ± 0.37 |
| Week 64 | -0.99 ± 0.52 |
The ACQ-5-IA had 5 questions addressing most common asthma symptoms: frequency in past week awoken by asthma during night, severity of asthma symptoms in morning, limitation of daily activities due to asthma, shortness of breath due to asthma and wheeze. Participants/parents/guardians recalled the child's previous week asthma and responded to symptom and bronchodilator use questions on a 7-point scale: 0=no impairment, 6=maximum impairment. Global ACQ-5-IA score was the mean of 5 questions, ranging from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control. Baseline: last available measurement prior to first study treatment dose if participant was treated, or last available value up to enrollment if participant was not exposed to study treatment in current study.
| score on a scale | Japan Sub-study: Dupilumab |
|---|---|
| Week 2 | -0.68 ± 0.87 |
| Week 4 | -0.75 ± 1.06 |
| Week 8 | -0.92 ± 0.82 |
| Week 12 | -1.20 ± 0.84 |
| Week 24 | -1.15 ± 0.68 |
| Week 36 | -1.25 ± 0.54 |
| Week 52 | -1.49 ± 0.54 |
| Week 64 | -1.28 ± 0.59 |
Blood samples were collected at the specified timepoints for determination of functional dupilumab concentration in serum.
| nanogram per milliliter | Main Study: Dupilumab 100 mg q2w | Main Study: Dupilumab 200 mg q2w | Main Study: Dupilumab 300 mg q4w | Japan Sub-study: Dupilumab 100 mg q2w | Japan Sub-study: Dupilumab 200 mg q2w | Japan Sub-study: Dupilumab 300 mg q4w |
|---|---|---|---|---|---|---|
| Week 12 | 60740.38 ± 23885.77 | 80450.15 ± 39865.24 | 79600.00 ± 25509.84 | 38600.00 ± 20850.18 | 79128.57 ± 24513.31 | 53066.67 ± 18569.96 |
| Week 24 | 64201.03 ± 22890.02 | 81849.66 ± 42824.93 | 80675.00 ± 26921.27 | 41300.00 ± 22138.65 | 98316.67 ± 18066.81 | 55166.67 ± 14558.96 |
| Week 52 | 52808.85 ± 21526.05 | 71910.74 ± 42290.54 | 81289.94 ± 31957.07 | 41000.00 ± 23157.94 | 91128.57 ± 28739.33 | 59300.00 ± 18107.46 |
| Week 64 | 1884.04 ± 9763.01 | 3391.86 ± 16196.36 | 184.69 ± 582.75 | 39.00 ± 0.00 | 39.00 ± 0.00 | 39.00 ± 0.00 |
ADA positive was defined as either treatment-boosted or treatment-emergent response in the ADA assay. Treatment-boosted response was defined as a positive response in the ADA assay post first dose in the current study that was greater than or equal to 4-fold of the baseline titer levels, when baseline results were positive. Treatment-emergent response was defined as a positive response in the ADA assay post first dose in the current study, when baseline results were negative or missing. Baseline (main study): original baseline of parent study EFC14153. Baseline (sub-study): last available measurement prior to first study treatment dose if participant was treated, or last available value up to enrollment if participant was not exposed to study treatment in current study.
| Participants | Main Study: Placebo-Dupilumab | Main Study: Dupilumab-Dupilumab | Japan Sub-study: Dupilumab |
|---|---|---|---|
| Treatment-boosted ADA Response | 1 | 0 | — |
| Treatment-emergent ADA Response | 10 | 7 | 2 |
Blood samples were collected at specified timepoints to assess percent change from baseline in eosinophil count. Baseline was defined as the original baseline of parent study EFC14153.
| percent change | Main Study: Placebo-Dupilumab | Main Study: Dupilumab-Dupilumab |
|---|---|---|
| Main Study: Percent Change From Baseline in Blood Eosinophil Count at Week 64 | 34.528 ± 207.067 | 29.769 ± 323.837 |
Blood samples were collected at specified timepoints to assess percent change from baseline in total IgE in serum. Baseline (main study): the original baseline of parent study EFC14153. Baseline (sub-study): last available measurement prior to first study treatment dose if participant was treated, or last available value up to enrollment if participant was not exposed to study treatment in current study.
| percent change | Main Study: Placebo-Dupilumab | Main Study: Dupilumab-Dupilumab | Japan Sub-study: Dupilumab |
|---|---|---|---|
| Percent Change From Baseline in Total Immunoglobulin (Ig) E in Serum at Week 64 | -76.9 ± -85.2 | -86.8 ± -91.4 | -75.0 ± -81.1 |
FeNO was analyzed using a NIOX instrument or similar analyzer using a flow rate of 50 milliliter per second. FeNO assessment was conducted prior to spirometry and following a fast of ≥1 hour. Baseline was defined as the last available measurement prior to first study treatment dose if participant was treated, or last available value up to enrollment if participant was not exposed to study treatment in the current study.
| parts per billion | Japan Sub-study: Dupilumab |
|---|---|
| Japan Sub-study: Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 64 | -8.3 ± 27.5 |
Collected over AEs: From first dose of study treatment (Day 1) up to 112 days post last dose of study treatment, approximately 64 weeks for main study and sub-study each. Deaths: From first dose of study treatment (Day 1) up to end of follow-up, approximately 353 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Main Study: Placebo-Dupilumab | 0/125 (0%) | 1/125 (0.8%) | 63/125 (50.4%) |
| Main Study: Dupilumab-Dupilumab | 0/240 (0%) | 6/240 (2.5%) | 108/240 (45%) |
| Japan Sub-study: Dupilumab | 0/13 (0%) | 4/13 (30.8%) | 13/13 (100%) |
| Event | Main Study: Placebo-Dupilumab | Main Study: Dupilumab-Dupilumab | Japan Sub-study: Dupilumab |
|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/125 | 0/240 | 2/13 |
| BronchitisInfections and infestations | 0/125 | 0/240 | 1/13 |
| InfluenzaInfections and infestations | 0/125 | 0/240 | 1/13 |
| PneumoniaInfections and infestations | 1/125 | 0/240 | 0/13 |
| ConstipationGastrointestinal disorders | 0/125 | 1/240 | 0/13 |
| Complicated AppendicitisInfections and infestations | 0/125 | 1/240 | 0/13 |
| Pulmonary TuberculosisInfections and infestations | 0/125 | 1/240 | 0/13 |
| Upper Respiratory Tract InfectionInfections and infestations | 0/125 | 1/240 | 0/13 |
| Radius FractureInjury, poisoning and procedural complications | 0/125 | 1/240 | 0/13 |
| AtelectasisRespiratory, thoracic and mediastinal disorders | 0/125 | 1/240 | 0/13 |
| Event | Main Study: Placebo-Dupilumab | Main Study: Dupilumab-Dupilumab | Japan Sub-study: Dupilumab |
|---|---|---|---|
| PyrexiaGeneral disorders | 3/125 | 5/240 | 6/13 |
| InfluenzaInfections and infestations | 7/125 | 13/240 | 5/13 |
| NasopharyngitisInfections and infestations | 12/125 | 21/240 | 5/13 |
| PharyngitisInfections and infestations | 12/125 | 15/240 | 5/13 |
| BronchitisInfections and infestations | 5/125 | 7/240 | 3/13 |
| DiarrhoeaGastrointestinal disorders | 7/125 | 10/240 | 2/13 |
| Covid-19Infections and infestations | 1/125 | 3/240 | 2/13 |
| Upper Respiratory Tract InfectionInfections and infestations | 5/125 | 19/240 | 2/13 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/125 | 2/240 | 2/13 |
| Tension HeadacheNervous system disorders | 0/125 | 0/240 | 2/13 |
Main study: safety population included all participants exposed to at least 1 dose or part of a dose of the study treatment during current study regardless of the amount of treatment administered. Sub-study: enrolled population included all participants who signed the informed consent/assent and had a treatment kit number allocated and recorded in the interactive voice response system/interactive web response system database, regardless of whether the treatment kit was received or not.
| Age, Continuous(years) | Main Study: Placebo-Dupilumab | Main Study: Dupilumab-Dupilumab | Japan Sub-study: Dupilumab | Total |
|---|---|---|---|---|
| Mean | 9.9 ± 1.6 | 9.9 ± 1.7 | 9.69 ± 1.11 | 9.89 ± 1.62 |
| Sex: Female, Male(Participants) | Main Study: Placebo-Dupilumab | Main Study: Dupilumab-Dupilumab | Japan Sub-study: Dupilumab | Total |
|---|---|---|---|---|
| Female | 46 | 85 | 4 | 135 |
| Male | 79 | 155 | 9 | 243 |
| Race/Ethnicity, Customized(Participants) | Main Study: Placebo-Dupilumab | Main Study: Dupilumab-Dupilumab | Japan Sub-study: Dupilumab | Total |
|---|---|---|---|---|
| Caucasian/White | 111 | 215 | 0 | 326 |
| Black/of African Descent | 6 | 9 | 0 | 15 |
| Asian | 0 | 1 | 13 | 14 |
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Other | 8 | 14 | 0 | 22 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Jun 2018 to primary completion in Apr 2025, 81 months.
Results were first posted in Nov 2025, 7 months after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 81 months is above that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab